FY2024 Earnings Estimate for VIRX Issued By Leerink Partnrs

Viracta Therapeutics, Inc. (NASDAQ:VIRX) – Investment analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Viracta Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.80) for the year, down from their previous forecast of ($0.69). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Viracta Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.40) EPS.

Other research analysts also recently issued research reports about the stock. Royal Bank of Canada dropped their target price on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Leerink Partners downgraded shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $3.00 in a report on Friday, August 16th.

Viracta Therapeutics Price Performance

Shares of VIRX opened at $0.15 on Monday. The company has a market capitalization of $5.96 million, a PE ratio of -0.14 and a beta of 0.72. Viracta Therapeutics has a one year low of $0.13 and a one year high of $1.31. The company’s fifty day moving average price is $0.22 and its 200 day moving average price is $0.42.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.